aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Kyle Wiggers
April 17, 2024
The U.S. Consumer Financial Protection Bureau (CFPB) said in an order on Tuesday that BloomTech, the for-profit coding bootcamp previously known as the Lambda School, deceived students about the cost of loans, made false claims about graduates’ hiring rates and engaged in illegal lending masked as “income sharing” agreements with high fees.
The order marks the end of the CFPB’s investigation into BloomTech’s practices and the start of the agency’s penalties on the organization.
The CFPB is permanently banning BloomTech from consumer lending activities and its CEO, Austen Allred, from student lending for a period of 10 years. In addition, the agency is ordering BloomTech and Allred to cease collecting payments on loans for graduates who didn’t have a qualifying job and allow students to withdraw their funds without penalty, as well as eliminate finance changes for “certain agreements.”
“BloomTech and its CEO sought to drive students toward income share loans that were marketed as risk-free, but in fact carried significant finance charges and many of the same risks as other credit products,” CFPB Director Rohit Chopra said in a statement. “Today’s action underscores our increased focus on investigating individual executives and, when appropriate, charging them with breaking the law.”
BloomTech and Allred must also pay the CFPB over $164,000 in civil penalties to be deposited in the agency’s victims relief fund, with BloomTech contributing around $64,000 and Allred forking over the remaining $100,000.
Allred founded BloomTech, which rebranded from the Lambda School in 2022 after cutting half its staff, in 2017. Based in San Francisco, the vocational organization is owned primarily by Allred but is backed by various VC funds and investors including Gigafund, Tandem Fund, Y Combinator, GV, GGV and Stripe. At one time it was valued at over $150 million.
Critics almost immediately attacked the firm’s then-pioneering business model — the income share agreement, or ISA — as predatory.
BloomTech originated “at least” 11,000 income-share loans to fund students’ tuition for the short-term, typically six-to-nine-month certification programs in fields spanning web development, data science and back-end engineering, according to the CFPB. These loans required that recipients who earned more than $50,000 in a related industry pay BloomTech 17% of their pre-tax income each month until reaching the 24-payment or $30,000 total repayment threshold.
BloomTech didn’t market the loans as loans, really, saying that they didn’t create debt and were “risk free” — and advertised a 71% to 86% job placement rate. But the CFPB found these marketing claims and others to be patently false.
BloomTech’s loans in fact carried an annual percentage rate and an average finance charge of around $4,000, neither of which students were made aware of, and a single missed payment triggered a default. The school’s job placement rates were closer to 50% and sank as low as 30%. And, unbeknown to many students, BloomTech was selling a portion of its loans to investors while depriving recipients of rights they should’ve had under a federal protection known as the Holder Rule.
Prior to the CFPB order, BloomTech, which briefly landed in hot water with California’s oversight board several years ago for operating without approval, had faced other lawsuits claiming the school misrepresented how likely graduates were to get a job and how much they were likely to earn. Last year, leaked documents obtained by Business Insider raised questions about the company inflating its efficacy and hyping up a curriculum that didn’t upskill students at the level they expected.
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: